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Abstract 
Background: Quinoline derivatives have diverse biological activities including anticancer activity. On the other hand, 
many sulfonamide derivatives exhibited good cytotoxic activity. Hybrids of both moieties may present novel antican‑
cer agents.
Results: Chloroquinoline incorporating a biologically active benzene‑sulfonamide moieties 5–21 and diarylsulfone 
derivatives 22 and 23 were prepared using (E)‑1‑(4‑((E)‑7‑chloro‑1‑methylquinolin‑4(1H)‑ylideneamino)phenyl)‑3‑
(dimethyl‑amino)prop‑2‑en‑1‑one 4 as strategic starting material. The structure of the newly synthesized compounds 
were confirmed by elemental analyses and spectral data. Compound 4 was confirmed by X‑ray crystallographic analy‑
sis. The prepared compounds were evaluated for their anticancer activity against Lung, HeLa, Colorectal and breast 
cancer cell lines. Compounds 2, 4, 7, 11, 14 and 17 showed better or comparable activity to 2′, 7′‑dichlorofluorescein 
(DCF) as reference drug. Molecular docking of the active compounds on the active site of PI3K enzyme was per‑
formed in order to explore the binding mode of the newly synthesized compounds.
Conclusion: Compounds 2, 4, 7, 11, 14 and 17 are novel quinoline derivatives that may represent good candidates 
for further evaluations as anticancer agents. The mechanism of action of these compounds could be through inhibi‑
tion of PI3K enzyme.
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Background
Quinoline scaffold has been broadly distributed in sun-
dry natural and synthetic compounds with multipur-
pose biological activities [1–3]. The antitumor activity of 
the quinoline derivatives for instance camptothecin [4], 
luotonin [5], ascididemin [6], TAS-103 A that displayed 
IC50 value of: 0.0030–0.23 microM hostile to various cell 
lines [7], CIL-102 B that unveiled IC50 value of: 0.31–2.69 
microM hostile to countless cell lines [8], cryptolepin 
[9] and indolo[2,3-b]quinolines [10] has been described. 
Numerous mechanisms of action were optional for such 
action among them was the strong suppression of E2F1 
that inhibits growth by thwarting cell cycle progres-
sion and fasters differentiation by creating a permissive 
environment for cell distinction [11]. Chloroquinolines 
were valuable in sundry cancer sorts remarkably, breast 
cancer with high aptitude to induce apoptosis [12]. Het-
erocyclic sulfonamides have publicized good anticancer 
bustle with diversity of mechanisms embracing cell cycle 
perturbation at G1 phase, disruption of microtubules 
assembly and the eminent carbonic anhydrase inhibition 
activity with selectivity to the tumor allied isoforms hCA 
IX and hCA XII [13–17]. Merging quinoline scaffold with 
the biologically active benzene-sulfonamide moiety has 
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received immense attention as PI3K inhibitor which is an 
vital enzyme regulatory signal transduction [16, 18–20]. 
Freshly, diaryl sulfones that were prepared from Dapson 
have shown respectable cytotoxic activity on breast can-
cer cell line [21]. Based on the aforementioned and as a 
continuation for our effort to synthesize a novel antican-
cer agents [18–25], we have prepared novel quinolone-
sulfonamide and diarylsulfone derivatives. Prepared 
compounds were subjected to cytotoxic assay on lung, 
hela, colorectal and breast cancer cell lines. Likewise, 
“the highest active compounds were docked on the active 
site of PI3K enzyme” to recommend their binding mode 
in a trial to explore their mechanism of action expecting 
to reach innovative anticancer agents.  
Results and discussion
Chemistry
The ambition of this effort was to prepare a new series 
of chloroquinolines carrying biologically active benzene-
sulfonamide moieties and to assess their anticancer 
activity. Thus, interaction of 2 [26] with dimethylforma-
mide-dimethylacetal (DMF-DMA) in dry xylene yielded 
the unexpected 4 instead of expected 3. “The structural 
assignments to synthesized compounds were based on 
their physico-chemical characteristics and spectroscopic 
(FT-IR, 1H-NMR, 13C-NMR, and mass spectroscopy) 
investigations”. Structure of 4 was confirmed by X-ray 
crystallographic analysis [27] (Figs. 1, 2). IR of 4 revealed 
the disappearance of NH band and presence of absorp-
tion bands for (aromatic), (aliphatic), (CO), (CN), (CCl). 
1H-NMR showed the presence of a singlet at 2.4  ppm 
attributed to N-(CH3)2, singlet at 3.4  ppm assigned to 
N-CH3, two doublet at 5.4, 6.5  ppm for CH  =  CH of 
quinolone ring, two doublet at 6.1,7.4  ppm assigned 
to CH  =  CH group. Enaminones are highly reactive 
intermediates extensively used for the preparation of 
heterocyclic derivatives. Thus, treatment of 4-(7-chloro-
1-methylquinolin-4-(1H)-ylideneamino) phenyl-3-
(dimethyl-amino)-prop-2-en-1-one 4 with sulfonamide 
derivatives in refluxing ethanol/acetic acid mixture (2:1) 
afforded the sulfonamide derivatives 5–21 (Scheme  1). 
“Structures of the latter products were assigned on the 
basis of their analytical and spectral data”. 1H NMR of 
5–21 support the assumption that these structures were 
in E-form and not in Z form, while the coupling con-
stant of doublet signals for olefinic protons was equal 
to 6.1–7.7  Hz. IR of the reaction products showed in 
each case three absorption bands for 2NH functions in 
the 3446–3143  cm−1 region, in addition to carbonyl 
functions 1654–1635  cm−1 region and CCl functions 
883–763  cm−1 (Scheme  1). 1H-NMR of 5 showed sin-
glet at 12.0 ppm assigned to NH group, while 13C NMR 
revealed singlet at 189.3  ppm for CO group. 1H-NMR 
of 6 exhibited singlet at 2.0  ppm according to COCH3 
group.1H-NMR of 7 revealed singlet at 9.4 ppm for NH 
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group. 1H-NMR of 8 showed singlet at 2.3 ppm for CH3 
group, while 1H NMR of 9 exhibited two signals at 1.9, 
2.6 assigned to 2CH3 groups. 1H NMR of 10 revealed two 
signals at 10.2, 12.0 ppm assigned to NH, SO2NH groups. 
1H-NMR of 11 exhibited two signals at 6.6, 6.8 ppm for 
CH = CH of thiazole ring. 1H-NMR of 12 exhibited sin-
glet at 2.4 ppm for CH3 of thiadiazole ring. 13C NMR of 
13 showed signal at 186.6  ppm due to CO group. 1H-
NMR of 15 exhibited singlet at 2.3 ppm for CH3 of pyrim-
idine ring. 1H-NMR of 16 revealed singlet at 2.2  ppm 
for 2CH3 of pyrimidine ring. 1H-NMR of compound 17 
exhibited singlet at 3.9  ppm for OCH3 group. 1H-NMR 
of 18 showed singlet at 3.7  ppm assigned to 2OCH3 
groups, while 1H NMR of 19 exhibited two signals at 
3.6, 3.8 ppm attributed to 2OCH3 groups. 1H NMR of 20 
revealed singlet at 12.0 according to NH group of inda-
zole ring. 13C-NMR of 21 showed singlet at 186.7  ppm 
for CO group. Interaction of 4 with Dapson in molar 
ratio (1:1  mol) afforded the mono compound 22, while 
the bis-compound 23 was achieved in the same condition 
but in molar ratio (2:1 mol). Compounds 22 and 23 were 
confirmed by microanalyses, IR, 1H-NMR, 13C-NMR and 
mass spectral data. IR of 22 revealed the characteristic 
bands at 3446, 3348, 3213  cm−1 (NH2, NH), 1635  cm−1 
(CO), 1591 cm−1 (CN), 1369, 1180 cm−1 (SO2), 821 cm−1 
(CCl). 1H-NMR of 22 exhibited signals at 3.4  ppm cor-
responding to N-CH3 group, 5.9 ppm due to NH2 group, 
two doublet at 6.1, 7.4 ppm for 2 CH quinoline, two dou-
blet at 6.5, 6.6 ppm assigned to CH = CH groups, singlet 
at 12.0 NH. 13C-NMR of 22 showed singlet at 186.6 ppm 
attributed to (CO) group. Mass of 22 revealed a molec-
ular ion peak m/z at 569 [M+] (19.87) with a base peak 
appeared at 90 (100). IR of 23 showed a characteristic 
bands at 3143 cm−1 (2NH), 1635 cm−1 (2CO), 1570 cm−1 
(2CN), 1375, 1180  cm−1 (SO2), 819  cm−1 (2CCl). 1H-
NMR of 23 revealed signals at 3.4 ppm for N-CH3, two 
doublets at 6.2, 7.3 ppm due to 4CH quinoline, two dou-
blets at 6.6, 7.2 assigned to 2CH =  CH, two singlet’s at 
9.3, 12.0 for 2NH groups. 13C-NMR of 23 revealed sin-
glet at 186.7 ppm for (2CO) groups. Mass of 23 showed 
a molecular ion peak m/z at 889 [M+] (6.48) with a base 
peak appeared at 272 (100) (Scheme 2).
In vitro cytotoxic screening
The newly synthesized compounds were evaluated for 
their in  vitro cytotoxic activity against human lung 
(A549-Raw), hela, colorectal (lovo) and breast (MDA-
MB231) cancer cell lines and 2′,7′-dichlorofluorescein 
(DCF) was used as the reference drug in this study. The 
relationship between surviving fraction and drug con-
centration was plotted to obtain the survival curve of 
cancer cell lines. The response parameter calculated 
was the IC50 value, which corresponds to the concentra-
tion required for 50 % inhibition of cell viability. Table 1 
shows the in  vitro cytotoxic activity of the newly syn-
thesized compounds. In a closer look to Table  1, we 
can see that compounds 1, 2, 4, 7, 11, 14 and 17 were 
active towards all the tested cell line while the rest of 
Fig. 2 Crystal packing of compound 4 showing the intermolecular hydrogen bonds
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compounds were inactive. Regarding the activity towards 
lung cancer cell line (A549-Raw), all the aforementioned 
compounds were more active than DCF as reference 
drug. Compound 2 was the most active compound with 
IC50 value of 44.34  μg/ml. For Hela cancer cell line, the 
same compounds were active. Compounds 7 and 17 
were more active than DCF and compound 17 was the 
most active compound with IC50 value of 30.92 μg/ml. In 
case of lovo cancer cell line, all seven compounds were 
more active than DCF. Compound 2 was the most active 
compound with IC50 value of 28.82  μg/ml. Finally, the 
activity towards breast cancer cell line (MDA-MB231) 
was better than that of DCF for the aforementioned 
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Scheme 1 Synthetic pathways for compounds 5–21
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again was the most active compound with IC50 value of 
26.54 μg/ml. In the light of biological results, we can see 
that the 4,7-dichloroquinoline 1 showed moderate anti-
cancer activity that were enhanced upon converting it 
to 1-(4-(7-chloloquinoline-4-ylamino) phenyl)ethanone 
2. The activity still exists upon preparation of (E)-1-(4-
((E)-7-chloro-1-methylquinolin-4(1H)-ylideneamino) 
phenyl)-3-(dimethylamino) prop-2-en-1-one 4. Further 
preparation of the sulfonamide derivatives 5–21 using 
various sulfa drugs only succeeded to obtain active 
derivatives with the guanidine derivative 7, the thia-
zole derivative 11, the pyrimidine derivative 14 and the 
5-methoxypyrimidine derivative 17. Combination with 
diaryl sulfone moieties as in compounds 22 and 23 did 
not yield active compounds.
Molecular docking
Phosphoinositide 3-kinases (PI3K) comprises an impor-
tant class of enzymes that phosphorylates the 3 hydroxyl 
group of inisitol and play a major role in signal transduc-
tion through the cell cycle. Targeting PI3K by inhibitors 
has become a well-known strategy in seeking for new 
anticancer agents [28]. Quinolinesulfonamide deriva-
tives were reported to express good inhibitory activ-
ity on PI3K enzyme [16]. In our present investigation 
and in a trial to suggest the mechanism of action of the 
active compounds, molecular docking of compounds 1, 
2, 4, 7, 11, 14 and 17 was performed on the active site 
of PI3K to explore their binding modes to amino acids 
of the active site of the enzyme. The protein data bank 
file (PDB: 3S2A) was selected for this purpose. The file 
contains PI3K enzyme co-crystallized with a quinoline 
ligand. All docking procedures were achieved by MOE 
(Molecular Operating Environment) software 10.2008 
provided by chemical computing group, Canada. Dock-
ing on the active site of PI3K enzyme was performed 
for all synthesized compounds. Docking protocol was 
verified by redocking of the cocrystallized ligand in the 
vicinity of the active site of the enzyme with energy score 
(S) = −29.8249 kcal/mol and root mean standard devia-
tion (RMSD)  =  1.9094 (Fig.  3). The quinoline ligand 
interacts with the active site of PI3K by six interactions: 
Val 882 with a hydrogen bond of 2.90 Å, Tyr 867 with a 
hydrogen bond of 3.33 Å, Asp 864 with a hydrogen bond 
of 3.33 Å, Lys 833 with a hydrogen bond of 3.33 Å, Ser 
806 with a hydrogen bond of 3.74 Å and Asp 841 with 
a hydrogen bond of 2.79 Å through a water molecule. 
All the docked compounds were fit in the active site of 
enzyme. Energy scores (S) as well as amino acids interac-
tions were listed in Table 2. The best docking score was 
achieved by compound 17 with a value = −27.1666 kcal/



































Scheme 2 Synthetic pathways for compounds 22 and 23
Table 1 In vitro anticancer screening of the newly synthe-














 1 68.74 84.20 84.26 77.78
 2 44.34 56.32 28.82 38.83
 4 76.73 88.66 104.78 72.85
 5 na na na na
 6 na na na na
 7 91.0 51.58 39.09 55.58
 8 na na na na
 9 na na na na
 10 na na na na
 11 97.27 91.74 81.89 111.90
 12 na na na na
 13 na na na na
 14 96.45 94.63 93.72 115.11
 15 na na na na
 16 na na na na
 17 47.31 30.92 31.27 26.54
 18 na na na na
 19 na na na na
 20 na na na na
 21 na na na na
 22 na na na na
 23 na na na na
 DCF 124.87 54.07 114.12 113.94
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hydrogen bond of 3.20 Å, with Asp 964 with a hydrogen 
bond of 2.48 Å, with Ser 806 with a hydrogen bond of 
3.38 Å and finally with His 984 with a hydrogen bond of 
2.70 Å (Figs. 4, 5).
Experimental
Chemistry
Melting points (uncorrected) were determined in open 
capillary on a Gallen Kamp melting point apparatus 
(Sanyo Gallen Kamp, UK). Precoated silica gel plates 
(Kieselgel 0.25  mm, 60 F254, Merck, Germany) were 
used for thin layer chromatography. A developing solvent 
system of chloroform/methanol (8:2) was used and the 
spots were detected by ultraviolet light. IR spectra (KBr 
disc) were recorded using an FT-IR spectrophotometer 
(Perkin Elmer, USA). 1H-NMR spectra were scanned on 
an NMR spectrophotometer (Bruker AXS Inc., Switzer-
land), operating at 500 MHz for 1H- and 125.76 MHz for 
13C. Chemical shifts are expressed in δ-values (ppm) rela-
tive to TMS as an internal standard, using DMSO-d6 as a 
solvent. Elemental analyses were done on a model 2400 
CHNSO analyser (Perkin Elmer, USA). All the values 
were within ±0.4 % of the theoretical values. All reagents 




(2.97  g, 0.01  mol) and dimethylformamide-dimethylac-
etal (1.19 g, 0.01 mol) was added into dry xylene (30 mL). 
Reaction was refluxed for 10  h, and the solid product 
recrystallized from ethanol to give 4.
Yield, 89 %; m.p.268.1 °C. IR: 3100 (arom.), 2966, 2856 
(aliph.), 1696 (CO), 1618 (CN), 776 (CCl).). 1HNMR: 
2.4 [s, 3H, N(CH3)2], 3.6 [s, 1H, N-CH3], 5.4, 6.5 [2d, 
2H, CH  =  CH quinoline, J  =  7.1, 7.3  Hz], 6.1,7.4 [2d, 
2H, CH = CH, J = 7.5, 7.4 Hz], 6.9–7.6 [m, 3H, Ar–H]. 
13CNMR: 36.3, 44.5 (2), 91.5, 114.6, 115.3, 116.9, 121.4 
(2), 131.7, 132.8 (2), 133.0, 135.9, 136.6, 141.4, 146.2, 
152.5, 161.4, 166.4, 191.3. MS m/z (%): 365 (M+) (2.84), 
74 (100). Anal.Calcd. For C21H20ClN3O (365.86): C, 68.94; 
H, 5.51; N, 11.49. Found: C, 68.66; H, 5.22; N, 11.74.
Fig. 3 Co‑crystallized quinoline ligand on the active site of phosphoinisitol kinase (PI3K)
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Table 2 Binding scores and  amino acid interactions of  the docked compounds on  the active site of  phosphoinisitol 
kinase (PI3K)
Compound no. S Kcal/Mol Amino acid interactions Interacting groups Type of interaction H bond length Å
1 −15.0154 Val 882 N‑quinoline H‑bond (acceptor) 2.87
2 −19.6829 Val 882 N‑quinoline H‑bond (acceptor) 3.5
Lys 802 CO H‑bond (acceptor) 2.42
Lys 890 Phenyl Arene‑cation
4 −15.8363 Val 882 CO H‑bond (acceptor) 2.58
7 −15.2630 Val 882 CO H‑bond (acceptor) 2.95
Asp 964 C = NH H‑bond (donor) 1.48
Lys 890 Phenyl Arene‑cation
11 −14.8730 Val 882 CO H‑bond (acceptor) 3.15
Lys 883 SO2 H‑bond (acceptor) 2.97
Ala 885 NH H‑bond (donor) 1.74
Glu 814 SO2NH H‑bond (donor) 1.34
14 −22.7755 Val 882 CO H‑bond (acceptor) 2.86
Lys 883 SO2 H‑bond (acceptor) 2.80
Lys 883 N‑pyrimidine H‑bond (acceptor) 3.00
Lys 890 Phenyl Arene‑cation
17 −27.1666 Val 882 N‑pyrimidine H‑bond (acceptor) 3.20
Asp 964 NH H‑bond (donor) 2.48
Ser 806 CO H‑bond (acceptor) 3.38
His 948 CN H‑bond (acceptor) 2.70
Fig. 4 2D interactions of compound 17 on the active site ofphosphoinisitol kinase (PI3K)
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Synthesis of sulfonamide derivatives 5–21
4-(7-chloro-1-methylquinolin-4-(1H)-ylideneamino) 
phenyl-3-(dimethylamino)-prop-2-en-1-one 4 (3.65  g, 
0.01  mol) and sulfa-drugs (0.012  mol) was added into 
ethanol (10 mL) and acetic acid (5 mL). The mixture was 
refluxed for 18 h. The solid product formed was recrys-




Yield, 88  %; m.p. 299.0  °C. IR: 3381, 3209 (NH2, NH), 
3078 (arom.), 2937, 2869 (aliph.), 1635 (CO), 1593 
(CN), 1373, 1182 (SO2), 867 (CCl). 1HNMR: 3.6 [s, 3H, 
N-CH3], 6.2, 7.3 [2d, 2H, 2CH quinoline, J  =  7.2  Hz], 
6.1, 7.6 [2d, 2H, CH = CH, J = 7.4 Hz], 7.7–8.6 [m, 13H, 
Ar–H + SO2NH2], 12.0 [s, 1H, NH]. 13CNMR: 40.5, 95.1, 
99.8, 104.9 (2), 112.5, 115.4, 116.2, 119.5 (2), 125.8 (2), 
127.9, 128.2 (2), 133.8, 137.6, 138.4, 143.1, 144.6, 146.7, 
152.5, 172.5, 189.3. MS m/z (%): 492 (M+) (4.72), 91 
(100). Anal. Calcd. For C25H21ClN4O3S (492.98): C, 60.91; 




Yield, 76 %; m.p. 310.0  °C. IR: 3367 (NH), 3066 (arom.), 
2939, 2877 (aliph.), 1724, 1635 (2CO), 1593 (CN), 
1369,1184 (SO2), 833 (CCl). 1HNMR: 2.0 [s, 3H, COCH3], 
3.5 [s, 3H, N-CH3], 6.3, 7.3 [2d, 2H, 2CH quinoline, 
J  =  7.4  Hz], 6.6, 7.6 [2d, 2H, CH  =  CH, J  =  7.6  Hz], 
7.7–8.6 [m, 12H, Ar–H  +  SO2NH], 12.0 [s, 1H, NH]. 
13CNMR: 23.6, 40.5, 97.8, 101.3, 112.7(2), 115.1, 116.0, 
119.5, 120.2 (2), 125.9 (2), 128.1, 129.5 (2), 130.2, 134.6, 
142.8 (2), 144.5, 146.9, 150.0, 152.4, 163.1, 186.7, 189.6. 
MS m/z (%): 535 (M+) (9.36), 74 (100). Anal. Calcd. For 
C27H23ClN4O4S (535.01): C, 60.61; H, 4.33; N, 10.47. 
Found: C, 60.29; H, 4.59; N, 10.19.
Fig. 5 3D interactions of compound 17 on the active site of phosphoinisitol kinase (PI3K)




Yield, 81  %; m.p. 146.6  °C. IR: 3431, 3336, 3209 (NH2, 
NH), 3100 (arom.), 2957, 2858 (aliph.), 1635 (CO), 1593 
(CN), 1373, 1178 (SO2), 827 (CCl). 1HNMR: 3.4 [s, 3H, 
NCH3], 6.2, 7.6 [2d, 2H, 2CH quinoline, J = 7.3 Hz], 6.1, 
7.4 [2d, 2H, CH  =  CH, J  =  7.4  Hz], 7.7–8.6 [m, 13H, 
Ar–H  +  NH2], 9.4 [s, 1H, NH imino], 10.3, 12.0 [2s, 
2H, NH  +  SO2NH]. 13CNMR: 40.5, 94.9, 99.4, 112.8 
(2), 115.2, 116.1, 119.5, 120.2 (2), 125.8 (2), 127.8, 129.5 
(2), 131.2, 133.8, 134.6, 138.0, 142.9, 144.8, 145.1, 158.2, 
158.5, 172.8, 189.2. MS m/z (%): 535 (M+) (7.74), 76 
(100). Anal. Calcd. For C26H23ClN6O3S (535.02): C, 58.37; 




Yield, 86  %; m.p. 192.5  °C. IR: 3446, 3215 (NH), 3088 
(arom.), 2970, 2883 (aliph.), 1635 (CO), 1616 (CN), 
1369,1159 (SO2), 821 (CCl). 1HNMR: 2.3 [s, 3H, CH3], 3.4 
[s, 3H, NCH3], 6.1, 7.3 [2d, 2H, 2CH quinoline, J = 7.7 Hz], 
6.6, 7.6 [2d, 2H, CH =  CH, J =  7.4  Hz], 6.7 [s, 1H, CH 
isoxazole], 7.7–8.5 [m, 12H, Ar–H + SO2NH], 12.0 [s,1H, 
NH]. 13CNMR: 12.4, 40.5, 95.5, 100.4, 104.7, 113.0 (2), 
115.5, 116.3, 119.5, 120.1 (2), 125.8, 129.2 (2), 132.9 (2), 
133.7, 134.6, 142.8, 144.9, 145.2, 146.8, 147.4, 153.7, 154.3, 
158.5, 170.5, 186.9. MS m/z (%): 574 (M+) (1.62), 58 (100). 
Anal. Calcd. For C29H24ClN5O4S (574.05): C, 60.68; H, 4. 




Yield, 77  %; m.p. 212.1  °C. IR: 3381, 3230 (NH), 3099 
(arom.), 2926, 2819, 2763 (aliph.), 1635 (CO), 1589 (CN), 
1373, 1180 (SO2), 810 (CCl). H1 NMR: 1.9, 2.6 [2s, 6H, 
2CH3], 3.4 [s, 3H, NCH3], 6.2, 7.3 [2d, 2H, 2CH quino-
line, J = 7.6 Hz], 6.6, 7.5 [2d, 2H, CH = CH, J = 7.5 Hz], 
7.6–8.6 [m, 11H, Ar–H], 10.4, 12.0 [2s,2H, NH +SO2NH]. 
13CNMR: 6.4, 10.8, 40.5, 95.5, 100.3, 102.9, 104.4 (2), 
115.5, 116.4, 119.2, 120.7 (2), 126.1, 127.3 (2), 129.5 (2), 
133.6, 134.1, 135.2, 142.9, 144.4, 145.4, 147.7, 157.4, 157.9, 
161.5, 172.5, 189.3. MS m/z (%): 588 (M+) (11.22), 55 
(100). Anal. Calcd. For C30H26ClN5O4S (588.08): C, 61.27; 




Yield, 80  %; m.p. 94.3  °C. IR: 3417, 3230 (NH), 3064 
(arom.), 2966, 2827 (aliph.), 1635 (CO), 1591 (CN), 1373, 
1180 (SO2), 763 (CCl). 1HNMR: 3.4 [s, 3H, NCH3], 6.2, 
7.5 [2d, 2H, 2CH quinoline, J = 7.5 Hz], 6.5, 7.2 [2d, 2H, 
CH  =  CH, J  =  7.7  Hz], 7.8–8.6 [m, 18H, Ar–H], 10.2, 
12.0 [2s, 2H, NH +SO2NH]. 13CNMR: 40.5, 97.3, 100.0, 
103.5, 111.6 (2), 113.0, 116.2, 118.6, 123.7 (2), 124.7 (2), 
125.1, 129.0 (2), 129.1, 129.2 (2), 129.3 (2), 129.4, 129.5, 
135.1, 136.2, 137.7, 138.9, 140.2, 142.7, 144.3, 146.1, 
156.8, 172.4, 186.8. MS m/z (%): 635 (M+) (4.43), 103 
(100). Anal. Calcd. For C34H27ClN6O3S (635.13): C, 64.30; 




Yield, 69  %; m.p. 172.7  °C. IR: 3341, 3219 (NH), 3101 
(arom.), 2937, 2869 (aliph.), 1635 (CO), 1589 (CN), 1373, 
1180 (SO2), 773 (CCl). 1HNMR): 3.4 [s, 3H, N-CH3], 
5.8, 7.6 [2d, 2H, 2CH quinoline, J = 7.0 Hz], 6.2, 7.2 [2d, 
2H, CH  =  CH, J  =  7.3  Hz], 6.6, 6.8 [2d, 2CH thiazole, 
J =  7.9 Hz], 7.7–8.6 [m, 11H, Ar–H], 10.2, 12.0 [2s, 2H, 
NH + SO2NH]. 13CNMR: 40.5, 95.1, 99.8, 108.5, 112.9(2), 
115.3, 116.2, 119.5, 120.1 (2), 125.9, 128.3 (2), 129.5 (2), 
133.0, 134.6, 135.7, 136.9, 143.0, 144.6, 145.1, 146.9, 
152.6, 168.4, 172.5, 186.6. MS m/z (%): 576 (M+) (8.99), 
101 (100). Anal. Calcd. For C28H22ClN5O3S2 (576.09): C, 




Yield, 82  %; m.p. 304.3  °C. IR: 3246, 3115 (NH), 3088 
(arom.), 2937, 2859 (aliph.), 1635 (CO), 1589 (CN), 1383, 
1182 (SO2), 769 (CCl). 1HNMR: 2.4 [s, 3H, CH3 thiadia-
zole], 3.4 [s, 3H, N-CH3], 6.2, 7.6 [2d, 2H, 2CH quinoline, 
J = 7.6 Hz], 6.6, 7.2 [2d, 2H, CH = CH, J = 7.8 Hz], 7.7–
8.5 [m, 11H, Ar–H], 10.3, 12.0 [2s, 2H, NH +  SO2NH]. 
13CNMR: 16.4, 40.5, 95.2, 99.9, 115.4 (2), 116.3, 120.2, 
120.4, 125.2 (2), 127.9, 128.2 (2), 129.5 (2), 133.1, 134.8, 
135.3, 143.0, 143.8, 144.6, 144.8, 152.1, 154.7, 168.3, 
172.4, 189.3. MS m/z (%): 591 (M+) (25.7), 178 (100). 
Anal. Calcd. For C28H23ClN6O3S2 (591.10): C, 56.89; H, 




Yield, 91  %; m.p. 177.1  °C. IR: 3323, 3219 (NH), 3080 
(arom.), 2939, 2849 (aliph.), 1654 (CO), 1596 (CN), 1375, 
1178 (SO2), 773 (CCl). 1HNMR: 3.4 [s, 3H, NCH3], 6.2, 
7.6 [2d, 2H, 2CH quinoline, J = 7.6 Hz], 6.6, 7.3 [2d, 2H, 
CH = CH, J = 7.1 Hz], 7.7–8.6 [m, 15H, Ar–H],10.3, 12.0 
[2s, 2H, NH +SO2NH]. 13CNMR: 40.5, 95.3, 100.0, 104.9, 
112.9 (2), 113.7, 115.3, 116.4, 119.5, 120.2 (2), 128.2, 
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129.5 (2), 132.9 (2), 133.7, 134.4, 135.7, 140.3, 142.9, 
143.9, 144.6, 145.2, 146.7, 152.4, 153.4, 172.5, 186.6. 
MS m/z (%): 570 (M+) (18.2), 79 (100). Anal. Calcd. For 
C30H24ClN5O3S (570.06): C, 63.21; H, 4. 24; N, 12. 29. 




Yield, 65  %; m.p. 212.9  °C. IR: 3367, 3179 (NH), 3078 
(arom.), 2937, 2870 (aliph.), 1635 (CO), 1577 (CN), 
1375,1178 (SO2), 883 (CCl). 1HNMR: 3.4 [s, 3H, 
N-CH3], 6.2, 7.3 [2d, 2H, 2CH quinoline, J  =  7.4  Hz], 
6.6, 7.6 [2d, 2H, CH = CH, J = 7.5 Hz], 7.0–8.6 [m, 15H, 
Ar–H + SO2NH], 12.0 [s, 1H, NH]. 13CNMR: 40.5, 95.5, 
100.3, 112.6 (2), 115.9, 116.0, 119.5, 120.2 (2), 125.8, 
128.1 (2), 130.3 (2), 132.9, 133.7, 134.3, 134.6, 142.8, 
144.3, 145.2, 146.9, 157.6 (2), 157.7, 158.6, 172.5, 186.6. 
MS m/z (%): 571 (M+) (33.2), 158 (100). Anal. Calcd. For 
C29H23ClN6O3S (571.05): C, 60.99; H, 4. 06; N, 14.72. 




Yield, 78  %; m.p. 274.8  °C. IR: 3366, 3259 (NH), 3076 
(arom.), 2962, 2870 (aliph.), 1635 (CO), 1562 (CN), 1373, 
1182 (SO2), 773 (CCl). 1HNMR: 2.3 [s, 3H, CH3], 3.4 [s, 
3H, NCH3], 6.2, 7.6 [2d, 2H, 2CH quinoline, J = 7.3 Hz], 
6.6, 7.3 [2d, 2H, CH = CH, J = 7.4 Hz], 7.5–8.5 [m, 13H, 
Ar–H], 10.3, 12.0 [2s, 2H, NH + SO2NH]. 13CNMR: 23.7, 
40.5, 95.4, 100.2, 104.9, 112.4 (2), 114.9, 115.2, 115.8, 
119.6 (2), 128.2, 129.5 (2), 130.5 (2), 132.9, 134.4, 134.6, 
142.8, 144.3, 145.3, 146.7, 152.4, 157.4, 158.0, 168.6, 
172.5, 186.6. MS m/z (%): 585 (M+) (9.36), 172 (100). 
Anal.Calcd. For C30H25ClN6O3S (585.08): C, 61.59; H, 




Yield, 91  %; m.p. 97.9  °C. IR: 3354, 3239 (NH), 3055 
(arom.), 2947, 2861 (aliph.), 1635 (CO), 1593 (CN), 1371, 
1180 (SO2), 864 (CCl). 1HNMR: 2.2 [s, 6H, 2CH3], 3.4 [s, 
3H, NCH3], 5.8, 7.2 [2d, 2H, 2CH quinoline, J = 7.3 Hz], 
6.6, 7.7 [2d, 2H, CH = CH, J = 7.5 Hz], 7.8–8.5 [m, 13H, 
Ar–H  +  SO2NH], 12.0 [s, 1H, NH]. 13CNMR: 23.4 (2), 
40.2, 95.3, 100.1, 104.7, 112.3 (2), 113.8, 114.6, 115.4, 
120.6 (2), 125.7, 129.4 (2), 130.8 (2), 132.9, 133.7, 134.8, 
144.8, 145.0, 146.9, 157.1, 167.7, 167.8 (2), 172.7, 189.3. 
MS m/z (%): 599 (M+) (2.71), 109 (100). Anal. Calcd. For 
C31H27ClN6O3S (599.10): C, 62.15; H, 4. 54; N, 14.03. 




Yield, 84  %; m.p. 264.5  °C. IR: 3396, 3221 (NH), 3101 
(arom.), 2979, 2865 (aliph.), 1637 (CO), 1593 (CN), 1371, 
1178 (SO2), 862 (CCl). 1HNMR: 3.4 [s, 3H, NCH3], 3.9 [s, 
3H, OCH3], 5.9, 7.4 [2d, 2H, 2CH pyrimidine, J = 7.1 Hz], 
6.2, 7.3 [2d, 2H, 2CH quinoline, J = 7.8 Hz], 6.6, 7.6 [2d, 
2H, CH = CH, J = 7.4 Hz], 7.7–8.6 [m, 11H, Ar–H], 10.3, 
12.0 [2s, 2H, NH +  SO2NH]. 13CNMR: 40.5, 56.7, 95.4, 
100.2, 105.0 (2), 112.6, 115.1, 116.0, 119.6 (2), 125.8, 128.2 
(2), 129.8 (2), 130.1, 133.7, 134.6, 142.8, 144.2, 144.9, 
145.3, 149.9, 151.7, 152.4, 153.3, 172.5, 186.6, 186.9. MS 
m/z (%): 601 (M+) (11.87), 74 (100). Anal. Calcd. For 
C30H25ClN6O4S (601.08): C, 59.95; H, 4.19; N, 13.98. 




Yield, 87  %; m.p. 232.6  °C. IR: 3387, 3201 (NH), 3097 
(arom.), 2980, 2839 (aliph.), 1635 (CO), 1589 (CN), 1352, 
1178 (SO2), 771 (CCl). 1HNMR: 3.4 [s, 3H, N-CH3], 3.7 [s, 
6H, 2OCH3], 5.9 [s, 1H, CH pyrimidine], 6.2, 7.3 [2d, 2H, 
2CH quinoline, J = 7.5 Hz], 6.6, 7.2 [2d, 2H, CH = CH, 
J = 7.8 Hz], 7.4–8.5 [m, 11H, Ar–H], 10.3, 12.0 [2s, 2H, 
NH  +  SO2NH]. 13CNMR: 40.5, 54.1, 54.9, 85.1, 95.6, 
100.4, 104.9 (2), 115.4, 116.2, 119.5, 120.2 (2), 128.1, 
129.8 (2), 132.7 (2), 132.9, 133.7, 134.6, 142.7, 144.2, 
144.9, 145.2, 152.3, 160.8, 161.0, 164.7, 172.0, 186.6. MS 
m/z (%): 631 (M+) (34.47), 154 (100). Anal. Calcd. For 
C31H27ClN6O5S (631.10): C, 59.00; H, 4.31; N, 13.32. 




Yield, 83  %; m.p. 110.5  °C. IR: 3365, 3230 (NH), 3095 
(arom.), 2941, 2863 (aliph.), 1635 (CO), 1577 (CN), 1375, 
1159 (SO2), 773 (CCl). 1HNMR: 3.4 [s, 3H, N-CH3], 3.6, 
3.8 [2s, 6H, 2OCH3], 6.2, 7.2 [2d, 2H, 2CH quinoline, 
J = 7.6 Hz], 6.6, 7.6 [2d, 2H, CH = CH, J = 7.7 Hz], 7.7–
8.4 [m, 11H, Ar–H], 8.5 [s, 1H, CH pyrimidine], 10.3, 
12.0 [2s, 2H, NH +  SO2NH]. 13CNMR: 40.5, 54.2, 56.5, 
95.3, 100.1, 112.6 (2), 115.8, 119.4, 120.8 (2), 127.9, 129.5 
(2), 130.2, 133.0 (2), 133.8, 134.7, 142.9, 144.7, 145.1, 
146.9, 149.8, 150.9, 152.0, 154.3, 161.7, 172.5, 186.6. MS 
m/z (%): 631 (M+) (22.13), 189 (100). Anal. Calcd. For 
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C31H27ClN6O5S (631.10): C, 59.00; H, 4.31; N, 13.32. 




Yield, 89  %; m.p. 100.1  °C. IR: 3374, 3231 (NH), 3086 
(arom.), 2978, 2848 (aliph.), 1635 (CO), 1589 (CN), 
1363, 1151 (SO2), 819 (CCl). 1HNMR: 3.4 [s, 3H, 
N-CH3], 5.8, 6.6 [2d, 2H, 2CH quinoline, J  =  7.2  Hz], 
6.2, 6.8 [2d, 2H, CH = CH, J = 7.5 Hz], 7.0–8.5 [m, 16H, 
Ar–H  +  SO2NH], 10.8, 12.0 [2s, 2H, 2NH]. 13CNMR: 
40.5, 91.1, 95.5, 100.4, 113.0, 115.1 (2), 115.4, 116.3, 
119.5, 119.6, 119.8, 120.0, 120.6, 125.8, 129.0 (2), 129.8 
(2), 132.1, 132.8, 133.5, 137.3, 140.7, 143.6, 144.3, 145.3, 
146.8, 147.0, 154.3, 173.4, 189.8. MS m/z (%): 609 (M+) 
(51.63), 117 (100). Anal. Calcd. For C32H25ClN6O3S 





Yield, 66  %; m.p. 209.9  °C. IR: 3334, 3212 (NH), 3064 
(arom.), 2981, 2863 (aliph.), 1635 (CO), 1591 (CN), 1375, 
1178 (SO2), 767 (CCl). 1HNMR: 3.4 [s, 3H, NCH3], 6.2, 
7.3 [2d, 2H, 2CH quinoline, J = 7.0 Hz], 6.6, 7.2 [2d, 2H, 
CH  =  CH, J  =  7.3  Hz], 7.5–8.6 [m, 16H, Ar–H], 10.3, 
12.0 [2s, 2H, NH + SO2NH]. 13CNMR: 40.5, 95.5, 100.3, 
112.7 (2), 115.1, 116.0, 119.5,120.2 (2), 125.1, 126.3, 127.2, 
127.3, 129.1, 130.1 (2), 131.1 (2), 132.8, 133.0, 133.8, 
134.7, 138.0, 138.1, 139.2, 140.3, 142.7, 144.3, 149.7, 
152.1, 169.6, 186.7. MS m/z (%): 621 (M+) (10.76), 177 
(100). Anal. Calcd. For C33H25ClN6O3S (621.11): C, 63.81; 




Compound 4 (3.65gm, 0.01  mol) and dapson (2.48  g, 
0.01 mol) was added into ethanol (10 mL) and acetic acid 
(5  mL). The reaction was refluxed for 9  h and the solid 
obtained while hot was recrystallized from dioxane to 
give 22.
Yield, 69  %; m.p. 95.2  °C. IR: 3446, 3348, 3213 (NH2, 
NH), 3100 (arom.), 2956, 2838 (aliph.), 1635 (CO), 1591 
(CN), 1369, 1180 (SO2), 821 (CCl). 1HNMR: 3.4 [s, 3H, 
NCH3], 5.9 [s, 2H, NH2], 6.1, 7.4 [2d, 2H, 2CH quinoline, 
J = 7.8 Hz], 6.5, 6.6 [2d, 2H, CH = CH, J = 7.9 Hz], 7.5–
8.6 [m, 15H, Ar–H], 12.0 [s, 1H, NH]. 13CNMR: 40.5, 95.5, 
100.3, 113.3 (2), 113.4, 115.8 (2), 116.6, 119.3, 125.8 (2), 
128.9 (4), 129.6 (2), 132.9 (3), 133.7, 135.9, 142.8, 144.2, 
145.2, 146.9, 152.4, 154.3, 172.5, 186.6. MS m/z (%): 569 
(M+) (19.87), 90 (100). Anal. Calcd. For C31H25ClN4O3S 





Compound 4 (7.30 gm, 0.02  mol) and Dapson (2.48  g, 
0.01 mol) was added into ethanol (20 mL) containing ace-
tic acid (10 mL). Reaction was refluxed for 12 h and the 
solid obtained while hot was recrystallized from acetic 
acid to give 23.
Yield, 60 %; m.p. 186.9 °C. IR: 3143 (NH), 3078 (arom.), 
2964, 2842 (aliph.), 1635 (CO), 1570 (CN), 1375, 1180 
(SO2), 819 (CCl). 1HNMR: 3.4 [s, 6H, 2N-CH3], 6.2, 7.3 
[2d, 4H, 4CH quinoline, J  =  7.7  Hz], 6.6, 7.2 [2d, 4H, 
2CH  =  CH, J  =  7.8  Hz], 7.4–8.5 [m, 22H, Ar–H], 9.3, 
12.0 [2s, 2H, 2NH]. 13CNMR: 40.5 (2), 95.8 (2), 100.7 (2), 
104.9 (2), 113.4 (4), 115.8 (2), 116.7 (2), 119.6 (4), 125.8 
(4), 129.7 (4), 132.8 (4), 133.6 (2), 134.6 (2), 142.6 (2), 
144.0 (2), 145.9 (2), 146.7 (2), 152.3 (2), 172.5 (2), 186.7. 
MS m/z (%): 889 (M+) (6.48), 272 (100). Anal. Calcd. 
For C50H38Cl2N6O4S (889.85): C, 67.49; H, 4.30; N, 9.44. 
Found: C, 67.83; H, 4.66; N, 9.12.
Anticancer screening
The cytotoxic activity in  vitro of the novel synthesized 
compounds was measured using the sulforhodamine B 
stain (SRB) assay and the method of Skehan et  al. [29]. 
The in  vitro anticancer screening was done at pharma-
cognosy Department, College of Pharmacy, King Saud 
University, Riyadh, Saudi Arabia. Cells were plated in 
96-multiwell plate (104 cells/well) for 24  h before treat-
ment with the compound(s) to allow attachment of cell 
to the wall of the plate. Test compounds were dissolved in 
dimethylsulfoxide. Different concentrations of the com-
pound under test (10, 25, 50, and 100  μΜ) were added 
to the cell monolayer. Triplicate wells were prepared 
for each individual concentration. Monolayer cells were 
incubated with the compound(s) for 48 h at 37 °C and in 
an atmosphere of 5 % CO2. After 48 h, cells were fixed, 
washed and stained for 30 min with 0.4 % (Wt/vol) SRB 
dissolved in 1  % acetic acid. Excess unbound dye was 
removed by four washes with 1 % acetic acid and attached 
stain was recovered with Trise-EDTA buffer. Color inten-
sity was measured using an enzyme-linked immuno-
sorbent assay ELISA reader. Optical density was read at 
510 nm. The relation between the surviving fraction and 
drug concentration was plotted to get the survival curve 
after the specified time The molar concentration required 
for 50 % inhibition of cell viability (IC50) was calculated 
and compared to the reference drug 2′,7′-dichlorofluo-
rescein (DCF). The results are given in Table 1.
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Molecular docking
“All the molecular modeling studies were carried out on 
an Intel Pentium 1.6  GHz processor, 512  MB memory 
with Windows XP operating system using Molecular 
Operating Environment (MOE, 10.2008) software. All 
the minimizations were performed with MOE until a 
RMSD gradient of 0.05 kcal mol−1 Å−1 with MMFF94X 
force field and the partial charges were automatically 
calculated. The protein data bank file (PDB: 3S2A) was 
selected for this purpose. The file contains PI3K enzyme 
co-crystallized with a quinoline ligand obtained from 
protein data bank. The enzyme was prepared for dock-
ing studies where: (i) Ligand molecule was removed from 
the enzyme active site. (ii) Hydrogen atoms were added 
to the structure with their standard geometry. (iii) MOE 
Alpha Site Finder was used for the active sites search in 
the enzyme structure and dummy atoms were created 
from the obtained alpha spheres. (iv) The obtained model 
was then used in predicting the ligand enzymes interac-
tions at the active site”.
Conclusion
In summary, we had synthesized a novel series of ben-
zene-sulfonamide derivatives. Seven products 1, 2, 4, 7, 
11, 14 and 17 presented sound anticancer activity hostile 
to lung (A594 Raw), hela, and colorectal (lovo) cancer cell 
lines with better or comparable activity to DCF. Moreo-
ver, molecular docking for these active compounds 
showed proper fitting on the active site of PI3K enzyme 
suggesting their action as inhibitors for this enzyme but 
more investigation should be carried out in the future to 
explore precisely the mechanism of the action of the syn-
thesized derivatives.
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